| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 01/06/2005 | US20050003370 Expression vector comprising nucleotide sequences coding membrane receptor proteins for use in identifying modulators for treatment and prevention of cell proliferative, nervous system, reproductive cardiovascular and inflammation disorders |
| 01/06/2005 | US20050003353 Production of adenine nucleotide translocator (ant), novel ant ligands and screening assays therefor |
| 01/06/2005 | US20050003352 Comprises recombinant mitochondrial transport protein for diagnosis, prevention and treatment of alzheimer's, diabetes, parkinson's, huntington's, cancers |
| 01/06/2005 | US20050002986 Drug/drug delivery systems for the prevention and treatment of vascular disease |
| 01/06/2005 | US20050002937 Anti-IL-12 antibodies, compositions, methods and uses |
| 01/06/2005 | US20050002933 Proliferation and/or differentiation of stem and progenitor cells from embryo or adult |
| 01/06/2005 | US20050002928 Treatment with anti-ErbB2 antibodies |
| 01/06/2005 | US20050002909 Methods and compositions for treating intervertebral disc degeneration |
| 01/06/2005 | US20050002906 Preferentially amplifying in tumors following cancer cell activation of specific gene regulatory region |
| 01/06/2005 | US20050002900 Inhibiting estradiol production in human adipocytes using interferon gamma and/or tumor necrosis factor antagonist and/or interleukin-1 antagonist; reducing side effects |
| 01/06/2005 | CA2531020A1 Cannabinoid receptor modulator |
| 01/06/2005 | CA2531019A1 Preventive/remedy for urinary disturbance |
| 01/06/2005 | CA2526487A1 Heterocyclic methyl sulfone derivative |
| 01/05/2005 | EP1493812A2 A truncated keratinocyte growth factor (KGF) having increased biological activity |
| 01/05/2005 | EP1493751A1 Process for producing immunoglobulins for intravenous administration and other immunoglobulin products |
| 01/05/2005 | EP1493744A1 Tropane analogs and methods for inhibition of monoamine transport |
| 01/05/2005 | EP1493743A1 Substituted bipiperidine intermediates and derivatives thereof |
| 01/05/2005 | EP1493742A1 Amine and amide derivatives as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders |
| 01/05/2005 | EP1493738A1 Epothilone derivatives |
| 01/05/2005 | EP1493735A1 Pyrimidine derivatives useful as selective cox-2 inhibitors |
| 01/05/2005 | EP1493732A1 Compounds capable of inhibiting immunocyte-related allergic immune reactions |
| 01/05/2005 | EP1493431A2 Use of an extract of bauhinia for the preparation of pharmaceutical and cosmetic compositions |
| 01/05/2005 | EP1493033A2 Sc6 for diagnosis of hypoxia related conditions |
| 01/05/2005 | EP1493028A2 Phage displayed pdz domain ligands |
| 01/05/2005 | EP1492811A1 Muteins of the c5a anaphylatoxin, nucleic acid molecules encoding such muteins, and pharmaceutical uses of muteins of the c5a anaphylatoxin |
| 01/05/2005 | EP1492803A1 New analogs of nitrobenzylthioinosine |
| 01/05/2005 | EP1492797A1 1-oxa-3-aza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the production thereof |
| 01/05/2005 | EP1492796A1 Substituted amino isoxazoline derivatives and their use as anti-depressants. |
| 01/05/2005 | EP1492795A1 1- or 3-thia-benzonaphthoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof |
| 01/05/2005 | EP1492794A1 Piperazine substituted aryl benzodiazepines and their use as dopamine receptor antagonists for the treatment of psychotic disorders |
| 01/05/2005 | EP1492793A1 New-4-(pyrrolopyrimidin-6-yl)benzenesulphonamide derivatives |
| 01/05/2005 | EP1492789A1 Tropane derivatives as ccr5 modulators |
| 01/05/2005 | EP1492788A1 Indole-amid derivatives which possess glycogen phosphorylase inhibitory activity |
| 01/05/2005 | EP1492787A2 (condensed) pyrimidone and (condensed) pyridone compounds, processes for their preparation, and pharmaceutical compositions containing them |
| 01/05/2005 | EP1492786A1 Pyridinoylpiperidines as 5-ht1f agonists |
| 01/05/2005 | EP1492785A1 New compounds |
| 01/05/2005 | EP1492784A2 Substituted 2,3-diphenyl pyridines |
| 01/05/2005 | EP1492780A1 5-substituted 1,1-dioxo-[1,2,5]thiazolidine-3-one derivatives as ptpase 1b inhibitors |
| 01/05/2005 | EP1492779A1 Thiazole derivatives having cb1-antagonistic, agonistic or partial agonistic activity |
| 01/05/2005 | EP1492778A1 (4,2-disubstituted-thiazol-5-yl)amine compounds as pde7 inhibitors |
| 01/05/2005 | EP1492777A1 Thiazolidine-4-carbonitriles and analogues and their use as dipeptidyl-peptidase inhibitors |
| 01/05/2005 | EP1492775A2 Oxo-azabicyclic compounds |
| 01/05/2005 | EP1492772A1 Farnesyl protein transferase inhibitors as antitumor agents |
| 01/05/2005 | EP1492771A1 Quinoline and isoquinoline derivatives, method for the production thereof and use thereof as anti-inflammatory agents |
| 01/05/2005 | EP1492769A2 Novel process |
| 01/05/2005 | EP1492765A2 Novel gamma secretase inhibitors |
| 01/05/2005 | EP1492757A1 (2-((2-alkoxy)-phenyl)-cyclopent-1-enyl) aromatic carbo- and heterocyclic carboxylic acid and derivatives |
| 01/05/2005 | EP1492756A1 Novel thyroid receptor ligands |
| 01/05/2005 | EP1492571A2 Radiolabelled quinoline and quinolinone derivatives and their use as metabotropic glutamate receptor ligands |
| 01/05/2005 | EP1492568A1 Cancer treatment method comprising administration of an erb-family inhibitor and a raf and/or ras inhibitor |
| 01/05/2005 | EP1492567A1 Formulations and methods of using nitric oxide mimetics in cancer treatment |
| 01/05/2005 | EP1492559A2 Truncated 24 kda basic fibroblast growth factor |
| 01/05/2005 | EP1492555A2 Compositions and methods for modulation of effects on phagocyte and lymphoid cell population |
| 01/05/2005 | EP1492549A1 Compositions and methods for augmenting kidney function |
| 01/05/2005 | EP1492541A1 Pharmaceutical compositions comprising a 11-beta hydroxysteroid dehydrogenase inhibitor and a diuretic agent |
| 01/05/2005 | EP1492540A1 The use of devazepide as analgesic agent |
| 01/05/2005 | EP1492539A1 Statin therapy for enhancing cognitive maintenance |
| 01/05/2005 | EP1492536A1 4-(n-phenylamino)-quinazolines / quinolines as tyrosine kinase inhibitors |
| 01/05/2005 | EP1492534A1 Carbamic acid compounds comprising a piperazine linkage as hdac inhibitors |
| 01/05/2005 | EP1492533A1 N-substituted pyridinone and pyrimidinone derivatives for use as lp-pla2 inhibitors in the treatment of artherosclerosis |
| 01/05/2005 | EP1492532A1 Combinations of epinastine, belladonna and pseudoephedrine as new pharmaceutical formulations |
| 01/05/2005 | EP1492530A1 Thiazol-2-yl-imine compounds as pde-7 inhibitors |
| 01/05/2005 | EP1492526A2 Improved prodrugs of cc-1065 analogs |
| 01/05/2005 | EP1492522A1 Ansamycin formulations and methods for producing and using same |
| 01/05/2005 | EP1492501A1 Methods of using lamellar bodies for therapeutic purposes |
| 01/05/2005 | EP1492415A2 Method of improving absorption of vitamin e by a pet animal |
| 01/05/2005 | EP1492414A2 Method and dietary composition for improving fat digestibility |
| 01/05/2005 | EP1492413A2 Method and dietary composition for improving lipid digestibility |
| 01/05/2005 | EP1397386A4 Chimeric proteins for cell targeting and apoptosis induction and methods of using the same |
| 01/05/2005 | EP1397138B1 ACTIVE INGREDIENT COMBINATION (e.g. galanthamine or desoxypeganine with acamprosate or Memantine) FOR TREATING A DEPENDENCE ON ADDICTIVE SUBSTANCES OR NARCOTICS |
| 01/05/2005 | EP1226126B1 Pyrimidine derivatives |
| 01/05/2005 | EP1109537B1 Immediate release oral formulation comprising peptide thrombin inhibitors and a combination of microcrystalline cellulose and sodium starch glycollate |
| 01/05/2005 | EP1015449B1 (hetero)aryl-sulfonamide derivatives, their preparation and their use as factor xa inhibitors |
| 01/05/2005 | EP0996619B1 Tropane analogs and methods for inhibition of monoamine transport |
| 01/05/2005 | EP0996451B1 Triterpene saponin analogs having adjuvant and immunostimulatory activity |
| 01/05/2005 | EP0957914B1 Formulation of 5-ht agonists |
| 01/05/2005 | EP0912196B9 Use of a thexaphyrin in the preparation of a medicament for use with a chemotherapeutic agent in cancer chemosensitization |
| 01/05/2005 | DE19957065B4 Screening-Verfahren für Arzneistoffe A screening method for drugs |
| 01/05/2005 | DE10326187A1 Zellen als Träger für Bakterien Cells as carriers for bacteria |
| 01/05/2005 | DE102004028805A1 Mittel zur Förderung der Collagenbildung Means to promote collagen formation |
| 01/05/2005 | CN1561394A Muteins of human neutrophil gelatinase-associated lipocalin and related proteins |
| 01/05/2005 | CN1561393A Inhibitors of glycogen synthase kinase-3 (GSK-3) for treating glaucoma |
| 01/05/2005 | CN1561340A Novel 1, 2, 4-triazole compound |
| 01/05/2005 | CN1561336A Phenyl-piperazine derivatives as serotonin reuptake inhibitors |
| 01/05/2005 | CN1561334A Indole derivatives as COXII inhibitors |
| 01/05/2005 | CN1561246A Compositions of cyclooxygenase-2 selective inhibitors and radiation for inhibition or prevention of cardiovascular disease |
| 01/05/2005 | CN1561228A Enhancing organ maturity in neonates and predicting their duration of intensive care |
| 01/05/2005 | CN1561227A Method for treating hepatitis C virus infection in treatment failure patients |
| 01/05/2005 | CN1561222A Matrix metalloprotease inhibitor |
| 01/05/2005 | CN1561221A Novel medicinal herbal composition for treating liver diseases and HIV |
| 01/05/2005 | CN1561220A Method for the treatment of inflammation |
| 01/05/2005 | CN1561219A Pharmaceutical compounds |
| 01/05/2005 | CN1561216A Novel compounds |
| 01/05/2005 | CN1561215A Salts of substituted 1, 2, 3, 4-tetrahydroquinoline-2-carboxylic acid compounds used as nmda antagonist |
| 01/05/2005 | CN1561212A Benzimidazolidinone derivatives as muscarinic agents |
| 01/05/2005 | CN1561211A Nociceptin analogs |
| 01/05/2005 | CN1561207A Therapeutic delivery of carbon monoxide |
| 01/05/2005 | CN1561204A Use of COX-2 inhibitors for preventing immunodeficiency |
| 01/05/2005 | CN1561199A Pharmaceutical composition comprising lipids comprising a polar and a nonpolar moiety |
| 01/05/2005 | CN1561164A 抗微生物剂 Antimicrobial agent |